---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-024880"
form_type: "8-K"
ticker: "LNSR"
cik: "0001320350"
company_name: "LENSAR, Inc."
filed_at: "2022-06-30T23:59:59+00:00"
generated_at: "2026-06-24T21:55:24.554525+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# LENSAR holds commercial launch meeting for ALLY System after FDA clearance

## Summary
- LENSAR (LNSR) held commercial launch meeting week of June 27, 2022 for ALLY Adaptive Cataract Treatment System.
- Company expects to place 8 to 12 ALLY Systems in a controlled initial launch starting Q3 2022.
- ALLY launched with phacoemulsification features disabled; second 510(k) delayed due to predicate device withdrawal.
- Supply chain constraints delayed raw material delivery; wider U.S. availability planned for 2023.
- LENSAR plans to file CE Mark application in 2022 to commercialize ALLY in the European Union.

## SEC filing metadata
- accession: 0001564590-22-024880
- form_type: 8-K
- ticker: LNSR
- cik: 0001320350
- company_name: LENSAR, Inc.
- filed_at: 2022-06-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1320350/000156459022024880/0001564590-22-024880-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1320350/000156459022024880/lnsr-8k_20220627.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-024880
- JSON: https://secwatch.observer/filing/0001564590-22-024880.json
- Plain text: https://secwatch.observer/filing/0001564590-22-024880.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.